A Non-interventional, Prospective Study With Benralizumab
← catalyst calendarNCT06422078 · readout in 499 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
300estimated
Sites
41
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-25 | actual | When the study began enrolling |
| Primary completion | 2027-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-05-20 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma, Bronchial
Primary outcomes
what the primary-completion date above is the date OFChange in Asthma Control Test (ACT) total score in patients from baseline to week 12, 24 and 52 after first benralizumab dose
measured From baseline to week 12, 24 and 52
Proportion of responders at baseline, week 12, 24 and 52 after first benralizumab dose, using ACT
measured At baseline, week 12, 24 and 52
Change in daily doses of prescribed inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose
measured From baseline to week 12, 24 and 52
Change in daily doses of patient-reported inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose
measured From baseline to week 12, 24 and 52
Reduction (in percentage) in prescribed daily ICS dose intake from baseline to week 52 after first benralizumab dose
measured From baseline to week 52
Reduction (in percentage) in patient-reported daily ICS dose intake from baseline to week 52 after first benralizumab dose
measured From baseline to week 52
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed